kaiva,
Thank you for your excellent responses.
CED allowing for delivery of up to 30x the virus with a wider distribution certainly makes sense to me.
Ah, this is one I *wish* I could answer, though my best guess is backed up by my investment. If I recall correctly, the HC protocol addresses the low permeability issue by using multiple injections per patient and various techniques to guide those needles to known sites of tumor growth.
My money is also betting on good life extension. I believe Dr. Thompson stated something to the effect of "the longer the wait, generally means the better the results".
Oncolytics management does seem to feel that the FDA's suggestion was a good one from the viewpoint of maximizing efficacy. But of course it sent them back to the lab for another series of lab experiments and animal trials, which are far more time-consuming than most investors seem to think.
People certainly get discouraged easily when progress takes longer than a day. However, if the pump delivers increased efficacy, could it lead to drug approval at an earlier stage of the trial?
Earlier approval could effectively result in a "wash" in terms of overall time, but also provide for a more effective treatment option with greater acceptance, and higher pricing for the treatment. A win for patients and shareholders.
Thank you for the heads up re: the board.
P.S. Long awaited news today was nice.
AI
